Surgery Partners, Inc.

SGRY

Nasdaq; healthcare; SIC 8062, Services-General Medical & Surgical Hospitals, NEC; CIK 0001638833

D/E

on the D/E boundary of 370 graded peers in healthcare

rank 301 of 370; percentile 81.3; sampling error 2.5 points; lower is stronger



D/E, the sloth



Scoreboard	
Profitability	D percentile 63.9
Solvency	D/E percentile 80.8
Growth and financing	B percentile 36.1
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $8.1B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	late filer not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Mar 2, 2026 235 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	$15.94 2026-10-22; market equity $2.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 2, 2026

Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company." We are a leading healthcare services company with an integrated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 63.9						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(4.4%)	(6.6%)	63.9	812	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 4					
Solvency, sleeve percentile 80.8					
Twelve-month failure probability	not computable	0.06%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.30)			
one or more required annual facts are missing					
Net debt to EBITDA	5.95x	1.82x	87.8	75	2025-12-31
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	1.87x	2.96x	73.8	840	2025-12-31
Growth and financing, sleeve percentile 36.1					
Revenue growth, three-year compound	9.2%	10.1%	52.5	414	2025-12-31
Free cash flow growth, three-year compound	35.7%	10.9%	26.3	96	2025-12-31
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	6.7%	2.1%	37.4	705	2025-12-31
Net share issuance, one year	1.4%	2.4%	28.2	633	2026-02-23

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
296	Voyager Therapeutics, Inc. (VYGR)	79.9	D/E	short runway
297	Lucid Diagnostics Inc. (LUCD)	80.2	D/E	dilution
298	Personalis, Inc. (PSNL)	80.5	D/E	
299	Lexicon Pharmaceuticals, Inc. (LXRX)	80.8	D/E	fortress balance sheet
300	Merck & Co., Inc. (MRK)	81.0	D/E	
301	Surgery Partners, Inc. (SGRY)	81.3	D/E	late filer
302	C4 Therapeutics, Inc. (CCCC)	81.6	D/E	dilution, fortress balance sheet
303	Hyperfine, Inc. (HYPR)	81.8	D/E	
304	Accuray Inc. (ARAY)	82.1	D/E	late filer
305	Moderna, Inc. (MRNA)	82.4	D/E	
306	SkinHealth Systems Inc. (SKIN)	82.7	E	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-22 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(35.8%)	8.0%	20
Distance from 52-week high	(30.7%)	(29.6%)	48
EBIT to enterprise value	7.1%	(1.5%)	87
Free cash flow yield	9.4%	(0.9%)	91
Book value to price	0.80	0.27	81
Sales to price	1.59	0.30	88
Composite equity issuance, five years	78.3%	20.5%	73
Relative strength against the sector, log excess return	(0.66)	(0.13)	20

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$216.7M
Operating cash flow, four quarters	$258.0M
Months of runway	not finite
Days since last periodic filing	74 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	$25.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$1.8B	2019-12-31	2022-03-01	10-K	22-000019
2	cost of revenue	us-gaap:CostOfRevenue	$1.4B	2019-12-31	2020-03-13	10-K	20-000012
3	assets	us-gaap:Assets	$5.0B	2019-12-31	2021-03-10	10-K	21-000034
4	net income	us-gaap:NetIncomeLoss	-$77.9M	2025-12-31	2026-03-02	10-K	26-000008
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$274.3M	2025-12-31	2026-03-02	10-K	26-000008
6	assets	us-gaap:Assets	$8.1B	2025-12-31	2026-03-02	10-K	26-000008
7	assets	us-gaap:Assets	$7.9B	2024-12-31	2026-03-02	10-K	26-000008
8	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$3.6B	2025-12-31	2026-03-02	10-K	26-000008
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$239.9M	2025-12-31	2026-03-02	10-K	26-000008
10	operating income	us-gaap:OperatingIncomeLoss	$389.5M	2025-12-31	2026-03-02	10-K	26-000008
11	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$176.0M	2025-12-31	2026-03-02	10-K	26-000008
12	current assets	us-gaap:AssetsCurrent	$1.2B	2025-12-31	2026-03-02	10-K	26-000008
13	current liabilities	us-gaap:LiabilitiesCurrent	$615.5M	2025-12-31	2026-03-02	10-K	26-000008
14	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$3.3B	2025-12-31	2026-03-02	10-K	26-000008
15	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$3.1B	2024-12-31	2026-03-02	10-K	26-000008
16	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$2.7B	2023-12-31	2026-03-02	10-K	26-000008
17	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$2.5B	2022-12-31	2025-03-07	10-K	25-000053
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$78.7M	2025-12-31	2026-03-02	10-K	26-000008

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$300.1M	2024-12-31	2026-03-02	10-K	26-000008
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$90.4M	2024-12-31	2026-03-02	10-K	26-000008
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$293.8M	2023-12-31	2026-03-02	10-K	26-000008
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$88.8M	2023-12-31	2026-03-02	10-K	26-000008
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$158.8M	2022-12-31	2025-03-07	10-K	25-000053
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$80.6M	2022-12-31	2025-03-07	10-K	25-000053
25	assets	us-gaap:Assets	$6.9B	2023-12-31	2025-03-07	10-K	25-000053
26	assets	us-gaap:Assets	$6.7B	2022-12-31	2024-02-26	10-K	24-000029
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	129,419,836	2026-02-23	2026-03-02	10-K	26-000008
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	127,613,091	2025-02-24	2025-03-07	10-K	25-000053

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.